Showing results (31-40 of 344) with videos related to
Sort By:
Pageof 35
Antiviral Research|December 1, 1994
Treatment of acyclovir-unresponsive cutaneous herpes simplex virus infection with topically applied SP-303S Safrin, G McKinley, M McKeough, et al.Infection and Immunity|September 1, 1972
Growth of Newcastle disease virus and rubella virus in rheumatoid and nonrehumatoid synovial cell culturesS L Spruance, C B Smith, J Krall, et al.Cancer|January 15, 1985
Value of open-lung biopsy in 87 immunocompromised patients with pulmonary infiltratesB D Cheson, W E Samlowski, T T Tang, et al.Pharmacotherapy|January 1, 1989
Lack of ocular changes with dimethyl sulfoxide therapy of sclerodermaH H Shirley, M K Lundergan, H J Williams, et al.Antiviral Research|June 1, 1985
Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine creamD J Freeman, S L Sacks, E De Clercq, et al.The Journal of Infectious Diseases|June 26, 2001
Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot studyS L Spruance, S K Tyring, M H Smith, et al.The Western Journal of Medicine|May 1, 1979
Clinical and virologic course of herpes simplex genitalisZ A Brown, E R Kern, S L Spruance, et al.The Journal of Infectious Diseases|March 1, 1996
Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 diseaseJ D Kriesel, S L Spruance, R A Daynes, et al.Arthritis and Rheumatism|May 1, 1975
DNA polymerase activity of cultured rheumatoid synovial cellsS L Spruance, O C Richards, C B Smith, et al.Journal of Neurovirology|February 26, 2004
STAT1 binds to the herpes simplex virus type 1 latency-associated transcript promoterJohn D Kriesel, Brandt B Jones, Kimberly M Dahms, et al.Pageof 35